• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

性别差异对肾细胞癌手术治疗患者的临床病理特征和生存的影响:多中心 CORONA 数据库分析。

Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database.

机构信息

Department of Urology, St. Elisabeth Hospital Straubing, Straubing, Germany.

出版信息

World J Urol. 2013 Oct;31(5):1073-80. doi: 10.1007/s00345-013-1071-x. Epub 2013 Apr 9.

DOI:10.1007/s00345-013-1071-x
PMID:23568445
Abstract

PURPOSE

To investigate gender differences in clinicopathological features and to analyze the prognostic impact of gender in renal cell carcinoma (RCC) patients undergoing surgery.

METHODS

A total of 6,234 patients (eleven centers; Europe and USA) treated by radical or partial nephrectomy were included in this retrospective study (median follow-up 59 months; IQR 30-106). Gender differences in clinicopathological parameters were assessed. Multivariable Cox regression models were applied to determine the influence of parameters on disease-specific survival (DSS) and overall survival (OS).

RESULTS

A total of 3,751 patients of the study group were male patients (60.2 %), who were significantly younger at diagnosis and received more frequently NSS than women. Significantly, more often high-grade tumors and simultaneous metastasis were present in men. Whereas tumor size and pTN stages did not differ between genders, clear-cell and chromophobe RCC was diagnosed less frequently, but papillary RCC more often in men. Gender also independently influenced DSS (HR 0.75, p < 0.001) and OS (HR 0.80, p < 0.001) with a benefit for women. However, inclusion of gender in multivariable models did not significantly gain predictive accuracies (PA) for DSS (0.868-0.870, p = 0.628) and OS (0.775-0.777, p = 0.522). Furthermore, no significantly different DSS and OS rates were found in patients undergoing NSS.

CONCLUSIONS

This study demonstrates important gender differences in clinicopathological features and outcome of RCC patients with improved DSS and OS for women compared to men, even if solely patients with clear-cell RCC or M0-stage are taken into evaluation. However, inclusion of gender in multivariable models does not significantly gain PA of multivariable models.

摘要

目的

探讨肾细胞癌(RCC)患者手术治疗中性别差异的临床病理特征,并分析其对预后的影响。

方法

本回顾性研究共纳入 6234 例(来自 11 个中心,分布在欧洲和美国)接受根治性或部分肾切除术的患者(中位随访时间 59 个月,IQR 30-106)。评估了临床病理参数中的性别差异。应用多变量 Cox 回归模型确定参数对疾病特异性生存(DSS)和总生存(OS)的影响。

结果

研究组共 3751 例男性患者(60.2%),诊断时年龄较小,接受肾部分切除术的比例高于女性。男性中更常出现高级别肿瘤和同时转移。虽然肿瘤大小和 pTN 分期在性别间无差异,但男性中透明细胞和嫌色细胞 RCC 诊断较少,而乳头状 RCC 诊断较多。性别独立影响 DSS(HR 0.75,p<0.001)和 OS(HR 0.80,p<0.001),女性受益更多。然而,将性别纳入多变量模型并未显著提高 DSS(0.868-0.870,p=0.628)和 OS(0.775-0.777,p=0.522)的预测准确性。此外,在接受肾部分切除术的患者中,DSS 和 OS 率无显著差异。

结论

本研究表明,RCC 患者的临床病理特征和结局存在重要的性别差异,与男性相比,女性的 DSS 和 OS 得到改善,即使仅对透明细胞 RCC 或 M0 期患者进行评估也是如此。然而,将性别纳入多变量模型并不会显著提高多变量模型的预测准确性。

相似文献

1
Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database.性别差异对肾细胞癌手术治疗患者的临床病理特征和生存的影响:多中心 CORONA 数据库分析。
World J Urol. 2013 Oct;31(5):1073-80. doi: 10.1007/s00345-013-1071-x. Epub 2013 Apr 9.
2
Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.嫌色细胞肾细胞癌(RCC):大型多中心系列中的肿瘤学结果和预后因素。
BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.
3
Gender-specific clinicopathological features and survival in patients with renal cell carcinoma (RCC).肾细胞癌(RCC)患者的性别特异性临床病理特征和生存情况。
BJU Int. 2012 Jul;110(2 Pt 2):E28-33. doi: 10.1111/j.1464-410X.2011.10667.x. Epub 2011 Nov 15.
4
Clear cell and non-clear cell renal cell carcinoma in young adults: clinicopathological features, survival outcomes and prognostic factors.年轻成人肾透明细胞癌和非透明细胞癌:临床病理特征、生存结局和预后因素。
World J Urol. 2024 May 31;42(1):364. doi: 10.1007/s00345-024-05028-8.
5
The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013.2006年至2013年手术切除后孤立性淋巴结转移肾细胞癌的自然病史。
Urol Oncol. 2019 Dec;37(12):932-940. doi: 10.1016/j.urolonc.2019.08.003. Epub 2019 Sep 27.
6
ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma.ABO 血型是接受肾细胞癌手术患者生存的预测因子。
BJU Int. 2012 Dec;110(11 Pt B):E641-6. doi: 10.1111/j.1464-410X.2012.11366.x. Epub 2012 Sep 7.
7
Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).肾细胞癌肾切除术后 5 年以上复发相关特征:基于大型多中心数据库(CORONA/SATURN 项目)开发和内部验证预测晚期复发的风险模型(PRELANE 评分)。
Eur Urol. 2013 Sep;64(3):472-7. doi: 10.1016/j.eururo.2012.06.030. Epub 2012 Jun 22.
8
Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.在实施部分肾切除术的时代,肾细胞癌的组织学亚型对生存率有显著影响。
Urol Oncol. 2016 Jun;34(6):259.e1-8. doi: 10.1016/j.urolonc.2016.01.005. Epub 2016 Mar 2.
9
Relevance of Positive Surgical Margins in Localized Renal Cell Carcinoma After Surgical Resection: Predictive Factors and Survival Implications.手术切除后局限性肾细胞癌中阳性手术切缘的相关性:预测因素和生存意义。
Clin Genitourin Cancer. 2024 Aug;22(4):102110. doi: 10.1016/j.clgc.2024.102110. Epub 2024 May 1.
10
Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.肾细胞癌的保留肾单位手术:预测患者预后的临床病理特征
Urology. 2003 Oct;62(4):641-6. doi: 10.1016/s0090-4295(03)00489-8.

引用本文的文献

1
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impact.解读肾细胞癌免疫治疗结果:来自日本一项关于CANLPH评分影响的多机构研究的见解。
World J Urol. 2025 Feb 24;43(1):135. doi: 10.1007/s00345-025-05507-6.
2
A Comprehensive Analysis of the Effect of Histological Subtypes on the Survival Probability of Kidney Carcinoma Patients: A Hypertabastic Survival Analysis.组织学亚型对肾癌患者生存概率影响的综合分析:超弹性生存分析
J Ren Cancer. 2020;3(1):20-33. doi: 10.36959/896/604. Epub 2020 Dec 28.
3
Sex differences in renal cell carcinoma: a single-cell analysis reveals exhausted CD8 T-cells highly infiltrated in males.

本文引用的文献

1
Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series.术前血小板计数和血小板增多症是否对接受肾细胞癌肾切除术的患者具有预后作用?一项综合回顾性系列研究的结果。
World J Urol. 2013 Oct;31(5):1309-16. doi: 10.1007/s00345-012-0931-0. Epub 2012 Aug 19.
2
Age and gender related differences in renal cell carcinoma in a European cohort.欧洲队列中肾细胞癌的年龄和性别相关差异。
J Urol. 2012 Jul;188(1):33-8. doi: 10.1016/j.juro.2012.02.2573. Epub 2012 May 12.
3
Gender-specific clinicopathological features and survival in patients with renal cell carcinoma (RCC).
肾细胞癌的性别差异:单细胞分析揭示男性中高度浸润的耗尽 CD8 T 细胞。
Biol Sex Differ. 2023 Sep 15;14(1):58. doi: 10.1186/s13293-023-00540-9.
4
Molecular differences in renal cell carcinoma between males and females.男性和女性肾细胞癌之间的分子差异。
World J Urol. 2023 Jul;41(7):1727-1739. doi: 10.1007/s00345-023-04347-6. Epub 2023 Mar 11.
5
A Web-Based Prediction Model for Cancer-Specific Survival of Elderly Patients With Clear Cell Renal Cell Carcinoma: A Population-Based Study.基于网络的老年透明细胞肾细胞癌患者癌症特异性生存预测模型:一项基于人群的研究。
Front Public Health. 2022 Mar 3;9:833970. doi: 10.3389/fpubh.2021.833970. eCollection 2021.
6
Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence.肾癌中的性别差异:临床与实验证据
Cancers (Basel). 2021 Sep 13;13(18):4588. doi: 10.3390/cancers13184588.
7
Prognostic Molecular Signatures for Metastatic Potential in Clinically Low-Risk Stage I and II Clear Cell Renal Cell Carcinomas.临床低风险Ⅰ期和Ⅱ期透明细胞肾细胞癌转移潜能的预后分子特征
Front Oncol. 2020 Aug 11;10:1383. doi: 10.3389/fonc.2020.01383. eCollection 2020.
8
Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma.接受肾切除术的肾细胞癌患者中GRade、年龄、淋巴结和肿瘤(GRANT)评分对无病生存期的预测能力
Curr Urol. 2020 Jun;14(2):98-104. doi: 10.1159/000499252. Epub 2020 Jun 23.
9
Gender-Related Approach to Kidney Cancer Management: Moving Forward.性别相关的肾癌管理方法:展望未来。
Int J Mol Sci. 2020 May 10;21(9):3378. doi: 10.3390/ijms21093378.
10
Temporal Trends in Selecting Patients for Partial Nephrectomy for Small Renal Cell Carcinomas in Alberta, Canada.加拿大艾伯塔省小肾癌患者接受部分肾切除术的选择的时间趋势
Res Rep Urol. 2020 Mar 4;12:85-90. doi: 10.2147/RRU.S212584. eCollection 2020.
肾细胞癌(RCC)患者的性别特异性临床病理特征和生存情况。
BJU Int. 2012 Jul;110(2 Pt 2):E28-33. doi: 10.1111/j.1464-410X.2011.10667.x. Epub 2011 Nov 15.
4
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.α-甲基 CoA 消旋酶(AMACR)在肾细胞癌中的表达的预后价值。
World J Urol. 2013 Aug;31(4):847-53. doi: 10.1007/s00345-011-0783-z. Epub 2011 Oct 19.
5
CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma.CD133 免疫组化表达可预测肾细胞癌的进展和与癌症相关的死亡。
World J Urol. 2012 Aug;30(4):553-8. doi: 10.1007/s00345-011-0769-x. Epub 2011 Oct 4.
6
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.肾细胞癌的预后因素和预测模型:当代综述。
Eur Urol. 2011 Oct;60(4):644-61. doi: 10.1016/j.eururo.2011.06.041. Epub 2011 Jun 30.
7
The clinical characteristics of renal cell carcinoma in female patients.女性肾细胞癌患者的临床特征。
Int J Urol. 2009 Jun;16(6):554-7. doi: 10.1111/j.1442-2042.2009.02309.x. Epub 2009 May 12.
8
[Gender-specific characteristics and survival of renal cell carcinoma].[肾细胞癌的性别特异性特征与生存情况]
Urologe A. 2008 Sep;47(9):1182, 1184-6. doi: 10.1007/s00120-008-1832-0.
9
Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival.肾细胞癌发病率和生存率的种族/族裔及性别差异。
J Urol. 2008 May;179(5):1704-8. doi: 10.1016/j.juro.2008.01.027. Epub 2008 Mar 17.
10
Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993-2004.肾细胞癌临床表现及生存率的性别差异:对1993 - 2004年国家癌症数据库的分析
J Urol. 2008 May;179(5):1709-13; discussion 1713. doi: 10.1016/j.juro.2008.01.024. Epub 2008 Mar 17.